Advertisement
Advertisement
U.S. Markets close in 53 mins
Advertisement
Advertisement
Advertisement
Advertisement

Nova Mentis Life Science Corp. (NOVA.CN)

Canadian Sec - Canadian Sec Real Time Price. Currency in CAD
Add to watchlist
0.03500.0000 (0.00%)
As of 02:30PM EDT. Market open.
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0350
Open0.0350
Bid0.0350 x N/A
Ask0.0400 x N/A
Day's Range0.0350 - 0.0400
52 Week Range0.0300 - 0.1600
Volume293,227
Avg. Volume173,832
Market Cap3.903M
Beta (5Y Monthly)2.71
PE Ratio (TTM)N/A
EPS (TTM)-0.4520
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile

    Nova Mentis Psilocybin Microdose Capsule Formulation to be Submitted in Health Canada Phase 2A Clinical Trial Application

    Vancouver, British Columbia--(Newsfile Corp. - September 29, 2022) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce that the company has produced 1.5 mg psilocybin microdose capsules. These capsules were produced according to defined manufacturing processes and product speci

  • Newsfile

    Nova Mentis Completes Production of Psilocybin Microdose Capsules

    Company Plans to Submit Clinical Trial Application in Canada Vancouver, British Columbia--(Newsfile Corp. - September 15, 2022) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce that it has completed production of psilocybin microdose capsules in collaboration with the Toront

  • Newsfile

    Nova Mentis to Present Promising Psilocybin Microdose Data at 18th NFXF International Fragile X Conference

    Vancouver, British Columbia--(Newsfile Corp. - July 11, 2022) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce it will be discussing the therapeutic potential of oral microdose psilocybin for the treatment of autism spectrum disorder (ASD) and fragile X syndrome (FXS) durin

Advertisement
Advertisement